Pivotal Therapeutics issues correction to 2013 financial results press release

WOODBRIDGE, ON, May 1, 2014 /CNW/ - Pivotal Therapeutics Inc. (OTCQX: PVTTF) (CSE: PVO), a specialty pharmaceutical company with a focus on Omega-3 therapies for cardiovascular disease (CVD) and overall health, announces a correction to its press release issued yesterday entitled "Pivotal Therapeutics Announces 2013 Financial Results".

The decrease in the loss from 2012 to 2013 of $745,342 was inadvertently overstated by $91,520. The correct decrease in loss is $653,822 and not $745,342 as presented in the press release. All other information remains unchanged. The revised information is as follows:

"For the twelve months ended December 31, 2013 the Company reported a loss of $3.0 million, or $0.04 per common share, compared with a loss of $3.6 million, or $0.05 per common share for the twelve months ended December 31, 2012. The decrease in loss of $653,822 is attributed to the improvement in revenues combined with a reduction in operating expenses."

This correction applies only to the press release issued effective April 30, 2014.

About Pivotal Therapeutics Inc.

Pivotal Therapeutics is a publicly traded (OTCQX: PVTTF) (CSE: PVO) specialty pharmaceutical company with a focus on cardiovascular disease and overall health. Pivotal Therapeutics' lead product VASCAZEN^® is a prescription only medical food formulated to meet the dietary Omega-3 deficient needs of patients with cardiovascular disease through elevating Eicosapentaenoic acid (EPA) and Docosahexaenoic acid (DHA) to levels associated with reduced risk of cardiovascular complications. OMAZEN^® is a pharmaceutical grade Omega-3 providing over 90% pure Omega-3 in each capsule for the maintenance of good health. OMAZEN^® is a patented product available for sale and distribution in Canada.

About VASCAZEN^®

VASCAZEN^® is currently available in the U.S. as a prescription only medical food specifically formulated for the dietary management of an Omega-3 deficiency in cardiovascular patients. VASCAZEN^® is a >90% pure Omega-3 with a proprietary 6:1 EPA:DHA fatty acid formulation, protected by a series of both U.S. and foreign patents.

VASCAZEN^® has been clinically shown to correct an Omega-3 deficiency within eight weeks of treatment with positive concomitant effects on the lipid profiles, mainly a 48% reduction of triglycerides and an increase of HDL without negative impact on the LDL-C lipid profile. VASCAZEN^®'s results were achieved with a dose of 3 grams of EPA and DHA per day of a prescription grade, high purity Omega-3.

Disclosure Notice

The information contained in this document is as of May 1, 2014. This press release contains forward-looking statements. Such forward-looking statements are subject to a number of risks, assumptions and uncertainties that could cause Pivotal's actual results to differ materially from those projected in such forward-looking statements. These statements can be identified by the use of words such as "will", "anticipate", "estimate", "expect", "project", "forecast", "intend", "plan", "believe", "project", "potential", and similar expressions with any discussion of future operating or financial performance or events. In particular, factors that could cause actual results to differ materially from those in forward looking statements include the following: Pivotal's inability to obtain additional financing on acceptable terms; growth in costs and expenses; inability to compete with others who provide comparable products; risk that the Company's products will not gain widespread market acceptance; risks relating to the Company's ability to maintain its CSNX listing. Forward-looking statements speak only as of the date made and are not guarantees of future performance. The Company undertakes no obligation to publicly update or revise any forward-looking statements contained in this document as a result of new information or future events or developments. CNSX has not reviewed and does not accept responsibility for the adequacy or accuracy of this information.

SOURCE: Pivotal Therapeutics Inc.

Company Contacts: Rachelle MacSweeney, President and Chief Operating Officer, Phone: [phone], E-Mail: [email protected]; Kristine DiMatteo, Communications and Public Relations Manager, Phone: [phone] ext. 231, E-Mail: [email protected]; www.pivotaltherapeutics.us